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Abstract
Background: The respiratory microbiome is altered in COPD patients but its relationship with core components of
the disease, such as the severity of airflow limitation, the frequency of exacerbations or the circulating levels of
eosinophils, is unclear.
Methods: Cross-sectional study comprising 72 clinically stable COPD patients (mean age 68 [SD 7.9] years; FEV1
48.7 [SD 20.1]% of reference) who provided spontaneous sputum samples for 16S rRNA gene amplification and
sequencing. The microbiome composition was analysed with QIIME.
Results: We observed that: (1) more severe airflow limitation was associated with reduced relative abundance (RA)
of Treponema and an increase in Pseudomonas; (2) patients with ≥2 exacerbations the previous year showed a
significantly different bacterial community with respect to non-exacerbators (p = 0.014), with changes in 13 genera,
including an increase of Pseudomonas, and finally, (3) peripheral eosinophils levels ≥2% were associated with more
diverse microbiome [Chao1 224.51 (74.88) vs 277.39 (78.92) p = 0.006; Shannon 3.94 (1.05) vs 4.54 (1.06) p = 0.020],
and a significant increase in the RAs of 20 genera.
Conclusion: The respiratory microbiome in clinically stable COPD patients varies significantly according to the
severity of airflow limitation, previous history of exacerbations and circulating eosinophils levels.
Keywords: Bacterial community, Diversity, Eosinophils, Exacerbations, Sputum, Stable COPD
Summary at a glance
Core components of COPD such as airflow limi-
tation, history of previous exacerbations and level of
circulating eosinophils have an impact in the
bronchial respiratory microbiome of clinically stable
COPD patients.
Background
Chronic obstructive pulmonary disease (COPD) is a het-
erogeneous disease [1–3]. The study of the respiratory
microbiome in COPD has revealed a specific bacterial
community composition in these patients [4, 5].
However, the relationship between this microbiome and
core components of the disease, such as, the severity of
the airflow limitation and the type of treatment received
remains unclear. In addition, changes in the microbiome
have been described in COPD exacerbations [6, 7], but it
is not known if differences between patients who suffer
two or more exacerbations per year, who are considered
frequent exacerbators [8, 9], and non-exacerbators can
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be detected during clinical stability. Likewise, levels of
circulating eosinophils ≥2% in clinically stable patients
identifies a subgroup of COPD patients who are prone
to recurrent exacerbations and are more responsive to
treatment [10–12], but it is not clear if this is associated
with a different respiratory microbiome. This work
sought to investigate these questions.
Methods
Methods are detailed in the Additional file 1 and
summarized below.
Study design and ethics
This is a cross-sectional, prospective, uncontrolled, mul-
ticentre, observational study. The study protocol was ap-
proved by the Ethics Committees of the participating
hospitals (IMIM-Hospital del Mar, Hospital Universitari
Parc Taulí, Hospital Clinic, Hospital 12 Octubre, Funda-
ción Jimenez Díaz and Hospital Son Espases), and all pa-
tients included signed their informed consent.
Population
Current or former smokers (≥ 10 pack-year) with stable
COPD, attending the outpatients’ clinics of five Spanish
hospitals between 2014 and 2016 were included in this
study. The diagnosis and severity staging of COPD was
established in accordance with GOLD criteria [8]. Exclu-
sion criteria were: age less than 40 years; a lifetime diag-
nosis of asthma, cystic fibrosis, bronchiectasis or cancer;
patients receiving long-term treatment with oral cortico-
steroids or immunosuppressants; any comorbidity limit-
ing cognitive capabilities and ≥ 3 admissions or 1 episode
severe enough to require more than 30 days in hospital
the previous year. Patients who had been treated with
short-term antibiotics and/or corticosteroids at any time
during the previous three months were considered
unstable and not considered for the study.
Variables and measurements
Sociodemographic data were recorded by specific
questionnaires. Lung function values during stability
were obtained from the most recently available forced
spirometry with reversibility testing performed according
to standard techniques the previous year [13]. Peripheral
blood cell counts were obtained at enrolment and used
to identify patients with ≥2% circulating eosinophils
[14]. Episodes of increased dyspnoea, sputum production
and/or purulence during the previous year were identi-
fied and considered as exacerbations when treated with
antibiotics and/or corticosteroids [15, 16]. Participants
were considered as frequent exacerbators (FE) when they
reported ≥2 exacerbations the previous year.
Sample collection, DNA extraction, PCR amplification and
16S sequencing
Spontaneous sputum samples were collected and proc-
essed within 60min on the day of the visit. Sputum
quality was assessed according to Murray-Washington
criteria [17] and only samples with > 25 leucocytes per
field (M-W ≥ 3) were considered for the study. Sputum
samples were frozen until processing, which was carried
out in a certified BSL2 hood with appropriate laminar
flow.16S rRNA gene was amplified following the 16S
Metagenomic Sequencing Library Preparation Illumina
protocol (Part # 15044223 Rev. A, Illumina, CA, USA).
Details are provided in the Additional file 1.
Sequence analysis
The Quantitative Insights Into Microbial Ecology
(QIIME) pipeline 1.9.0 [18] was used for sequence
processing to obtain taxonomic information. Further
technical details are provided in the Additional file 1.
Statistical analyses
Details are provided in the Additional file 1. In brief, cat-
egorical variables are expressed as absolute and relative
frequencies, and continuous variables as means and
standard deviations (SD) when the distribution was
normal, or as medians and interquartile range (IQR)
otherwise. Linear discriminant analysis Effect Size
(LEfSe) was used to identify the differentially abundant
taxa that explained the differences between the groups
of participants. The threshold value of the logarithmic
LDA score for discriminative features was 2.0. Bacterial
α-diversity was assessed through the Chao1 estimator
[19] and the Shannon index [20], calculating both
indexes after subsampling with QIIME so as to avoid
sequencing effort bias. Principal Coordinates Analysis
(PCoA) with Bray-Curtis dissimilarity index [21] was
used to study community composition, assessing the
statistical significance of the differences in sample
groupings through Adonis testing. Interaction between
independent variables was assessed through stratification
and multivariate analyses with α-diversity as dependent
variable. Statistical tests used in the study were two-
sided, and a p value of 0.05 or less was reported as sta-
tistically significant. Statistical analyses were performed
using the SPSS statistical software package version 18
(SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Table 1 summarizes the main demographic and clinical
characteristics of the 72 patients included. They were
mostly men (88.9%), with a mean age of 68 (SD 7.9)
years and FEV1 of 48.7 (SD 20.1)% of reference.
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16S rRNA analysis
At phylum level, 13 different phyla were identified, six of
them with median relative abundance (RA) above 0.1%
(Additional file 1: Table S1). At genus level, 190 different
genera were identified and, after removing the genera
present in only one sample, 171 remained for subsequent
analyses, 26 of them with RA above 0.1% (Table 2).
Age
Alpha-diversity parameters showed a negative relationship
with age (R2 = 0.075 p = 0.020 and R2 = 0.074 p = 0.020 re-
spectively), but β-diversity analysis did not show signifi-
cant differences in relation with this variable (p = 0.389).
Airflow limitation
We found a significant progressive increase in the RA of
Pseudomonas genus and a decrease in the RA of
Treponema in patients with more severe airflow limita-
tion (Fig. 1). Regarding bacterial diversity, neither α-
diversity parameters nor β-diversity analysis showed
significant differences between GOLD grades of airflow
limitation. Of note, airflow limitation severity was not
related to age (p = 0.245).
Pharmacological treatment
Forty-nine COPD patients had not modified their inhaled
maintenance treatment during the previous year; thirty-
six of them (73.5%) used a combination of LAB/ICS, 9
(18.4%) were treated with LAB as monotherapy and 4
(8.2%) were not receiving COPD treatment. LAB/ICS
treatment did not have any effect on either α-diversity
(p = 0.365) or bacterial community composition in the
patients studied (p = 0.963), when compared with patients
not receiving this treatment. Similarly, the continuous use
of LAB as monotherapy was not associated with signifi-
cant changes in the respiratory microbiome (p = 0.854).
Exacerbation frequency
In the previous year, 31 patients (43.1%) did not report
any acute episodes, 18 (25%) referred only one and 23
suffered two or more (31.9%), and were considered FE.
Demographic and clinical characteristics of these three
groups only showed statistically significant differences in
lung function, with lower values in COPD patients
reporting one or more exacerbations the previous year
(Table 1) Comparisons between their respiratory
microbiomes were made in pairs using patients without
exacerbations as the reference. Patients with one exacer-
bation had significantly lower RA of the phylum TM7
(Additional file 1: Figure S1) and lower RAs of 13 differ-
ent genera (Additional file 1: Figure S2). However, α-
diversity parameters did not show significant differences
between the groups, and β-diversity analysis did not
demonstrate bacterial communities with a different
composition (p = 0.081). FE showed a significant
decrease in the RA of TM7 and Spirochaetes at phylum
level (Additional file 1: Figure S3). At genus level, the
RAs of Pseudomonas, Selenomonas and Anaerococcus
increased, while 10 different genera decreased (Fig. 2).
Alpha-diversity analysis did not show significant
differences between groups, but β-diversity analysis
demonstrated that the bacterial communities of
COPD patients with frequent exacerbations differed
significantly (p = 0.014).
Table 1 Demographic and clinical characteristics of the patients
N All patients Exacerbations previous year p
0 1 ≥2
72 31 18 23
Age, mean (SD) 68 (7.9) 66 (9) 69 (7) 68 (7) 0.387
Sex (male), n (%) 64 (88.9) 27 (87.1) 16 (88.9) 21 (91.3) 0.888
Cumulative smoking (pack-year), median (IQR) 60 (45–80) 60 (44–76) 50 (41–85) 60 (49–97) 0.383
Postbronchodilator FEV1%, median (IQR) 44 (33–60) 52 (42–70) 35 (32–52) 35 (28–49) 0.001
BMI, median (IQR) 27 (24–30) 28 (25–29) 28 (23–30) 26 (23–30) 0.669
Blood eosinophils (× 109/L), median (IQR) 200 (100–270) 200 (130–3009 185 (92–255) 200 (100–300) 0.414
Blood eosinophils (%), median (IQR) 2.4 (1.4–3.4) 2.8 (1.7–3.6) 2 (1.3–2.8) 1.8 (1.1–3.4) 0.156
Blood leucocytes (×109/L), median (IQR) 7845 (6635–9180) 7210 (6520–8940) 7915 (6505–8510) 8110 (7030–10,170) 0.481
Exacerbations last year, median (IQR) 1 (0–2) 0 1 3 (2–4)
Airflow limitation severity (GOLD), n (%)
GOLD 1 6 (8.3) 5 (16.1) 0 (0) 1 (4.3) 0.013
GOLD 2 19 (26.4) 11 (35.5) 4 (22.2) 4 (17.4)
GOLD 3 36 (50) 14 (45.2) 12 (66.7) 10 (11.1)
GOLD 4 11 (15.3) 1 (3.2) 2 (18.2) 8 (34.8)
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Circulating eosinophils
Forty-two of the participants (58.3%) had ≥2% blood
eosinophils. There were no significant differences in age
(p = 0.368), sex (p = 1.00) and number of exacerbations
the previous year (p = 0.080) between patients with ≥2%
circulating eosinophils or less. The bacterial community in
the former had significantly higher RAs of the phyla Bac-
teroidetes and Spirochaetes (Additional file 1: Figure S4).
At genus level, 20 genera showed significantly higher RA
and one genus, Peptostreptococcus, had lower RA in these
patients (Fig. 3). Alpha-diversity was significantly higher in
patients with ≥2% circulating eosinophils [Chao1 index:
224.51 (74.88) vs 277.39 (78.92), p = 0.006; and Shannon
index: 3.94 (1.05) vs 4.54 (1.06), p = 0.020] (Fig. 4). Pear-
son's correlation coefficients were r = 0.282 (p = 0.016) for
Chao1 and r = 0.231 (p = 0.051) for Shannon. β-diversity
analysis showed a trend towards different bacterial com-
munities (p = 0.072).
Multivariate analyses were performed with α-diversity
as dependent variable and eosinophils levels as predict-
ive factor, including age and lung function as covariates.
Eosinophils in blood, expressed as percentage, kept a
statistically significant relationship with Chao1 in this
analysis (p = 0.026) and a borderline significance for
Shannon (p = 0.051), a finding confirming that the
bronchial microbiome was related to blood eosinophils
independently of the functional limitations suffered by
the patient.
To explore potential interactions between the previous
history of exacerbations and eosinophils levels, we
compared the microbiome in COPD patients with and
without circulating eosinophils ≥2% stratified by the
frequency of exacerbations. We found that the signifi-
cant differences in the microbial composition related to
patients with eosinophils ≥2% were maintained in the
subsample of patients with no exacerbations or only one
episode (p = 0.033), but this effect disappeared in FE
(p = 0.995).
Table 2 Relative abundance of the genera detected. Only
genera appearing in more than one sample and with median
relative abundances over 0.1% are shown
Genera Relative abundance, median (IQR)
Rothia 18.65 (9.37–30.33)
Gemellaceae_g 7.32 (2.24–13.51)
Prevotella 6.87 (2.33–15.05)
Granulicatella 4.43 (2.16–6.58)
Fusobacterium 2.23 (0.26–3.93)
Porphyromonas 1.97 (0.13–8.22)
Actinomyces 1.80 (0.58–4.41)
Streptococcus 1.92 (1.23–3.44)
Pseudomonas 1.39 (0.40–6.36)
Veillonella 1.00 (0.50–1.44)
Atopobium 0.69 (0.30–1.56)
Oribacterium 0.62 (0.15–1.26)
Leptotrichia 0.51 (0.09–1.90)
Lachnospiraceae_g 0.50 (0.08–1.09)
[Prevotella] 0.44 (0.04–1.87)
Moryella 0.35 (0.06–0.94)
Campylobacter 0.35 (0.10–0.77)
Capnocytophaga 0.29 (0.01–0.99)
TM7-3_o_f_g 0.28 (0.04–1.45)
Megasphaera 0.25 (0.02–1.17)
Bulleidia 0.20 (0.05–0.85)
Haemophilus 0.19 (0.05–1.32)
Selenomonas 0.18 (0.04–0.62)
Parvimonas 0.11 (0.01–0.54)
Lactobacillus 0.12 (0.01–1.07)
Lactobacillales_Other_Other 0.11 (0.04–0.24)
Fig. 1 Genera showing significant differences in their relative abundance according to GOLD severity level, with higher figures for Treponema in
GOLD 1 (b) and for Pseudomonas in GOLD 4 (a) (dotted line =median)
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Discussion
The main findings of this study were that the diversity
and composition of the respiratory microbiome in clinic-
ally stable COPD patients change in relation to age, the
severity of airflow limitation, exacerbation frequency and
eosinophils in peripheral blood.
In our study, older age was significantly associated
with a loss of diversity, which has been also found in the
gut microbiome [22]. Besides, in patients with severe
asthma, an inverse correlation between α-diversity and
age has been also reported [23]. A previous work has
shown less microbial diversity of the respiratory micro-
biome in younger COPD patients using bronchoalveolar
lavage [24], but this sample targets the peripheral airway
of the lung and it is not representative of the bronchial
tree mainly sampled by sputum [25].
Fig. 2 The RA of three genera significantly increased (a) and 10 genera decreased (b) in patients with ≥2 exacerbations the previous year compared
with non-exacerbators (dotted line =median)
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Fig. 3 Genera with significantly higher (n = 20) (b) and lower (a) RAs (n = 1) in patients with circulating eosinophils ≥2% (dotted line = median)
Fig. 4 α-diversity parameters, Chao1 (a) and Shannon (b), in patients classified according to circulating eosinophils ≥2%
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We found that patients with more severe airflow
limitation had a significant decrease in the RA of
Treponema and a progressive increase in the RA of
Pseudomonas. These results suggest that severity-related
changes in the respiratory microbiome are based on a
decrease in specific genera, which are partially
substituted by Pseudomonas. This change may be partly
related to recurrent antibiotic exposure in previous
years, considering the antibiotic sensitivity of the micro-
organisms part of Treponema genus. Previous cross-
sectional studies evaluating the relation between bacter-
ial diversity and more severe airway limitation have
mostly showed a decline in advanced stages [26–28],
associated with changes in the RAs of specific genera
such as Haemophilus [28, 29]. These partly discordant
results may be due to patient selection, considering that
most of the previous studies have focused on a
restricted number of patients with moderate or severe
disease [26, 27] or an overrepresentation of patients
with moderate disease [28] whereas we studied a
wider range of disease severity (GOLD 1–4). Our
results, therefore, support a significant role for
Pseudomonas as the severity of the disease increases
to higher lung function impairment.
We also found that the respiratory microbiome was
significantly different in FE. Previous studies have inves-
tigated the characteristics of the respiratory microbiome
during exacerbations [7, 30], and recently, like we do in
this study, Mayhew and cols. [28] reported specific
characteristics in the bronchial microbiome recovered
from FE patients during clinical stability. Both studies
show that FE have a different respiratory microbiome
during clinical stability, suggesting that the microbial
changes during exacerbations in FE may be a mixture of
the dysbiosis found in stability and specific
exacerbation-related perturbations of the lung bacteria
community composition [28, 31].
Circulating eosinophils ≥2% were associated with
higher microbial diversity in the population studied.
Patients with ≥2% blood eosinophils have been reported
to have more frequent exacerbations and a better re-
sponse to ICS preventive therapy [32] Previous studies
have demonstrated a different bronchial microbiome in
eosinophilic COPD exacerbations [7, 31], which seems
related to Th2 inflammation in both COPD and asthma
[33]. In our study we observed that in patients with ≥2%
blood eosinophils higher microbial diversity is already
present in stability, with an increase in the RA of 20
genera. Similar results have been reported in stable
asthmatic patients, who showed a good correlation
between the percentage of eosinophils in bronchoalveo-
lar lavage and bacterial diversity [34]. Higher bacterial
diversity may have a protective role in patients with ≥2%
blood eosinophils avoiding the presence of pathogenic
bacteria such as Haemophilus influenzae and Streptococ-
cus pneumonia which has been reported to be overrep-
resented in patients with eosinophils counts below 2%
treated with ICS [12]. Yet, when we stratified the COPD
patients included according to both the level of circulat-
ing eosinophils and the frequency of exacerbations, we
observed that the differences related to blood eosino-
phils disappeared in FE, likely highlighting a higher
impact of frequent exacerbations on the respiratory
microbiome in these patients.
This study has some potential limitations. First, we do
not have a wide representation of the respiratory micro-
biome, which has been shown to be heterogeneous
throughout the airway, because only sputum samples
were analysed. Second, although the patients included
had not taken antibiotics three months before their
inclusion, we lack information on previous antibiotic
treatments, which may have had an effect on their mi-
crobial communities. Finally, we analysed only bacterial
communities, fungi and virus may also have an effect on
these patients, either directly or through interactions
with other microorganisms and the host.
Conclusions
This study shows that the respiratory microbiome in
clinically stable COPD patients changes in relation to
age, severity of airflow limitation, history of previous
exacerbations and level of circulating eosinophils. These
factors need to be considered when interpreting respira-
tory microbiome changes in patients with COPD.
Additional file
Additional file 1: Table S1. Relative abundances of the phyla detected.
Figure S1. The TM7 phylum had significantly lower relative abundance
in patients with one exacerbation than patients without exacerbations
the previous year (dotted line =median). Figure S2. Thirteen genera with
significantly lower relative abundances in COPD patients with one
exacerbation the previous year compared to non-exacerbators. Figure S3.
A significant reduction in the RA of phyla TM7 and Spirochaetes in
patients with ≥2 exacerbations the previous year, using patients
without exacerbations as the reference (dotted line = median).
Figure S4. Phyla with significantly higher relative abundances in
COPD patients showing circulating eosinophils ≥2%. (DOCX 725 kb)
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